Single-agent therapy with oral @entity4446 for nonlymphoid blast crisis of XXXX .

@entity1 @entity7275 @entity4446 @entity1503 @entity1860
Currently, no effective treatment is available for the nonlymphoid blast crisis (BC) of @entity1860 ( @entity1860 ) and because of this the prognosis for such @entity1 remains invariably poor. In an attempt to determine the results provided by palliative treatment with oral @entity4446 ( @entity7275 ) in the above @entity1503 , 30 such @entity1 were analyzed for hospital stay, days of intravenous (i.v.) antibiotics, transfusion requirements, response rate, and survival. Thirty @entity1 with nonlymphoid BC matched for their initial characteristics and treated with different i.v. regimens were used for comparison purposes. @entity1 managed with @entity7275 spent less days in hospital (median: 9, range: 0-46 vs median: 42, range: 5-140; P<0.0001), needed antibiotics for less days (median: 0. range: 0-46 vs median: 20, range: 0-57; P<0.0001), and received less platelet transfusions (median: 0, range: 0-20 vs median: 6, range: 0-63; P=0.004) than those treated with i.v. chemotherapy. Although no complete or partial remission was achieved by @entity1 receiving @entity7275 vs six in the i.v. chemotherapy group, no significant difference was observed when the survival of both groups was compared (median: 4.7 months, range: 0.1-22.7 vs median: 3.8 months, range: 0.2-12, respectively). These results indicate that @entity7275 therapy constitutes a good palliative treatment for @entity1 with nonlymphoid BC of @entity1860 . However, new treatment strategies for this @entity1503 are required.
